The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies
Authors
Keywords
-
Journal
mAbs
Volume 7, Issue 6, Pages 1084-1093
Publisher
Informa UK Limited
Online
2015-09-04
DOI
10.1080/19420862.2015.1075109
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
- (2015) Amita Datta-Mannan et al. mAbs
- Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
- (2015) Angela Schoch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- pH-dependent antigen-binding antibodies as a novel therapeutic modality
- (2014) T. Igawa et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge
- (2014) Bing Li et al. mAbs
- In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
- (2014) Vikas K. Sharma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
- (2013) Brian Gurbaxani et al. MOLECULAR IMMUNOLOGY
- Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo
- (2013) Tomoyuki Igawa et al. PLoS One
- Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics
- (2012) Daniela Bumbaca et al. AAPS Journal
- Monoclonal antibody therapeutics: history and future
- (2012) Nicholas APS Buss et al. CURRENT OPINION IN PHARMACOLOGY
- Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9
- (2012) Javier Chaparro-Riggers et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A strategy for risk mitigation of antibodies with fast clearance
- (2012) Isidro Hötzel et al. mAbs
- Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys
- (2012) Amita Datta-Mannan et al. mAbs
- Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences
- (2011) W. Wang et al. DRUG METABOLISM AND DISPOSITION
- Neonatal Fc receptor and IgG-based therapeutics
- (2011) Timothy T. Kuo et al. mAbs
- Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies
- (2011) Weirong Wang et al. MOLECULAR IMMUNOLOGY
- A Therapeutic Anti-VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
- (2010) Y. A. Yeung et al. CANCER RESEARCH
- Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study
- (2010) Y Zheng et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor- Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys
- (2010) R. Deng et al. DRUG METABOLISM AND DISPOSITION
- Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
- (2010) Takuo Suzuki et al. JOURNAL OF IMMUNOLOGY
- Charge variants in IgG1
- (2010) Leslie A. Khawli et al. mAbs
- Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
- (2010) Tomoyuki Igawa et al. NATURE BIOTECHNOLOGY
- Enhanced antibody half-life improves in vivo activity
- (2010) Jonathan Zalevsky et al. NATURE BIOTECHNOLOGY
- Reduced elimination of IgG antibodies by engineering the variable region
- (2010) T. Igawa et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Impact of Molecular Processing in the Hinge Region of Therapeutic IgG4 Antibodies on Disposition Profiles in Cynomolgus Monkeys
- (2009) K. Stubenrauch et al. DRUG METABOLISM AND DISPOSITION
- Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
- (2009) Y. A. Yeung et al. JOURNAL OF IMMUNOLOGY
- Molecular engineering and design of therapeutic antibodies
- (2008) Leonard G Presta CURRENT OPINION IN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started